ST Pharm Co.,Ltd.

KOSDAQ:A237690 Stock Report

Market Cap: ₩1.5t

ST PharmLtd Valuation

Is A237690 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A237690 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
₩66.34k
Fair Value
13.8% overvalued intrinsic discount
10
Number of Analysts

Below Fair Value: A237690 (₩75500) is trading above our estimate of fair value (₩66339.54)

Significantly Below Fair Value: A237690 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A237690?

Key metric: As A237690 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A237690. This is calculated by dividing A237690's market cap by their current earnings.
What is A237690's PE Ratio?
PE Ratio43.8x
Earnings₩34.71b
Market Cap₩1.52t

Price to Earnings Ratio vs Peers

How does A237690's PE Ratio compare to its peers?

The above table shows the PE ratio for A237690 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28.7x
A214370 Caregen
52.4x36.28%₩1.6t
A069620 Daewoong Pharmaceutical
42.2x34.98%₩1.6t
A185750 Chong Kun Dang Pharmaceutical
10.1x-6.71%₩1.1t
A003850 Boryung
10.2x0.28%₩707.8b
A237690 ST PharmLtd
43.8x25.62%₩1.5t

Price-To-Earnings vs Peers: A237690 is expensive based on its Price-To-Earnings Ratio (43.8x) compared to the peer average (28.7x).

Price to Earnings Ratio vs Industry

How does A237690's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
A096760 JW Holdings
3.6xn/aUS$165.51m
A000230 Ildong Holdings
1.2xn/aUS$54.46m
A007370 Jin Yang Pharmaceutical
2.4xn/aUS$53.95m
No more companies available in this PE range
A237690 43.8xIndustry Avg. 19.4xNo. of Companies10PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A237690 is expensive based on its Price-To-Earnings Ratio (43.8x) compared to the KR Pharmaceuticals industry average (19.4x).

Price to Earnings Ratio vs Fair Ratio

What is A237690's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A237690 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio43.8x
Fair PE Ratio29.8x

Price-To-Earnings vs Fair Ratio: A237690 is expensive based on its Price-To-Earnings Ratio (43.8x) compared to the estimated Fair Price-To-Earnings Ratio (29.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A237690 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩75,500.00
₩118,200.00
+56.56%
9.76%₩140,000.00₩100,000.00n/a10
May ’26₩79,000.00
₩118,200.00
+49.62%
9.76%₩140,000.00₩100,000.00n/a10
Apr ’26₩75,000.00
₩126,700.00
+68.93%
6.31%₩140,000.00₩112,000.00n/a10
Mar ’26₩76,500.00
₩126,700.00
+65.62%
6.31%₩140,000.00₩112,000.00n/a10
Feb ’26₩86,800.00
₩127,700.00
+47.12%
6.05%₩140,000.00₩112,000.00n/a10
Jan ’26₩88,900.00
₩127,700.00
+43.64%
6.05%₩140,000.00₩112,000.00n/a10
Dec ’25₩88,000.00
₩127,700.00
+45.11%
6.05%₩140,000.00₩112,000.00n/a10
Nov ’25₩95,700.00
₩127,700.00
+33.44%
6.05%₩140,000.00₩112,000.00n/a10
Oct ’25₩100,700.00
₩127,444.44
+26.56%
6.35%₩140,000.00₩112,000.00n/a9
Sep ’25₩115,000.00
₩123,000.00
+6.96%
9.42%₩140,000.00₩100,000.00n/a9
Aug ’25₩88,400.00
₩115,777.78
+30.97%
11.53%₩140,000.00₩100,000.00n/a9
Jul ’25₩89,800.00
₩111,333.33
+23.98%
13.01%₩140,000.00₩100,000.00n/a9
Jun ’25₩91,000.00
₩105,000.00
+15.38%
12.60%₩140,000.00₩100,000.00n/a8
May ’25₩93,400.00
₩105,555.56
+13.01%
11.91%₩140,000.00₩100,000.00₩79,000.009
Apr ’25₩90,100.00
₩104,444.44
+15.92%
12.85%₩140,000.00₩90,000.00₩75,000.009
Mar ’25₩63,600.00
₩104,444.44
+64.22%
12.85%₩140,000.00₩90,000.00₩76,500.009
Feb ’25₩63,400.00
₩105,000.00
+65.62%
12.23%₩140,000.00₩90,000.00₩86,800.0010
Jan ’25₩67,800.00
₩105,000.00
+54.87%
12.23%₩140,000.00₩90,000.00₩88,900.0010
Dec ’24₩63,600.00
₩110,909.09
+74.39%
16.06%₩150,000.00₩90,000.00₩88,000.0011
Nov ’24₩68,200.00
₩113,636.36
+66.62%
14.66%₩150,000.00₩100,000.00₩95,700.0011
Oct ’24₩76,400.00
₩122,000.00
+59.69%
10.87%₩150,000.00₩110,000.00₩100,700.0010
Sep ’24₩78,700.00
₩120,000.00
+52.48%
11.79%₩150,000.00₩100,000.00₩115,000.0011
Aug ’24₩76,800.00
₩119,230.77
+55.25%
11.14%₩150,000.00₩100,000.00₩88,400.0013
Jul ’24₩76,900.00
₩120,833.33
+57.13%
10.93%₩150,000.00₩100,000.00₩89,800.0012
Jun ’24₩88,800.00
₩120,833.33
+36.07%
10.93%₩150,000.00₩100,000.00₩91,000.0012
May ’24₩79,000.00
₩121,538.46
+53.85%
11.57%₩150,000.00₩100,000.00₩93,400.0013
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
₩118.20k
Fair Value
36.1% undervalued intrinsic discount
10
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/24 07:19
End of Day Share Price 2025/05/23 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ST Pharm Co.,Ltd. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yoonjin LimDaishin Securities Co. Ltd.
Heeyoung LeeDaishin Securities Co. Ltd.
Jisoo LeeDAOL Investment & Securities Co., Ltd.